Data are available from the Registrar of InfCareHIV: Veronica SvedhemJohansson Department of Infectious Diseases, Karolinska University Hospital, Huddinge SE-141 86, Stockholm Sweden. The Registrar will mediate the request for researchers who meet the criteria for access to confidential data to the steering committee of InfCareHIV.Email: <veronica.svedhem-johansson@karolinska.se>.

Introduction {#sec005}
============

Modern HIV treatment has transformed HIV from a fatal disease to a chronic condition. Since cure is not yet possible, combination anti-retroviral treatment (cART) must be lifelong. Despite the success of therapeutic developments in the past decades \[[@pone.0171227.ref001]\], there are still treatment challenges to overcome; among others transmitted drug resistance, adherence, drug to drug interactions and toxicity \[[@pone.0171227.ref002]--[@pone.0171227.ref006]\]. Performance and characteristics of antiretroviral (ARV) HIV drug efficacy is well described from randomized clinical trials. However, these trials include a highly selected patient population excluding individuals with anticipated non-adherence e.g. due to drug abuse or psychiatric diseases or patients with interfering concomitant diseases, thereby making the trial populations less representative than the real world patients \[[@pone.0171227.ref007]\].

To maximize long term treatment outcomes we need to identify the most durable treatment regimens and also investigate other factors independently associated with treatment duration. The Swedish database InfCareHIV includes high quality data from more than 99% of all patients diagnosed with HIV infection in Sweden and provides a unique opportunity to examine outcomes in a nationwide real world cohort \[[@pone.0171227.ref008]\].

All ARVs approved by the European Medicines Agency (EMA) are available and free of charge for HIV-infected individuals in Sweden. The Swedish HIV treatment guidelines are regularly updated, with the most recent updates being from 2009 \[[@pone.0171227.ref009]\], 2010 \[[@pone.0171227.ref010]\], 2011 \[[@pone.0171227.ref011]\], 2014 \[[@pone.0171227.ref012]\] and 2016 \[[@pone.0171227.ref013]\]. Start of first treatment in treatment-naïve patients has been recommended in all patients with a CD4 cell count \<350/μL from 2009, for all patients with CD4 cell count 350-500/ μL from 2011 and in all patients, irrespective of CD4 cell counts, from 2014. The recommended backbone nucleoside/nucleotide reverse transcriptase inhibitor (N\[t\]RTI) treatment in first line has been tenofovir disoproxil fumarate /emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), the latter as first alternative in combination with boosted protease inhibitors. Efavirenz (EFV) has been recommended as initial treatment already prior to 2009 and is also recommended in all following guidelines. Rilpivirine (RPV), launched in Sweden 2012, was included as an alternative for patients with HIV-RNA \<100 000 copies/mL from 2014. Among protease inhibitors (PIs), boosted atazanavir (ATV) and boosted darunavir (DRV) have been recommended from 2009 while lopinavir (LPV) was excluded as a first line recommendation from 2011 and onwards. Raltegravir (RAL) and dolutegravir (DTG) were included in recommended first line treatments from 2014. No specific recommendations are made in the guidelines regarding the choice of specific drugs in treatment experienced patients, in these the choice of treatment regime is individualized taking into account different variables like reason for switch, prior treatment history, drug resistance and comorbidities.

The aim of the present study was to investigate treatment duration for 3^rd^ agents and factors that might influence duration, in the nationwide HIV cohort in Sweden. Third agents constitute all ARVs that are not N\[t\]RTIs and that are added to a backbone regimen (BR) of usually two N\[t\]RTIs. Treatment duration is the time from starting a new 3^rd^ agent to the discontinuation of the same 3^rd^ agent. Treatment duration was chosen as the primary effect outcome as this is a key proxy measure, reflecting the effectiveness, tolerability and convenience of a drug. This study includes all treatment-naïve and treatment-experienced patients from the national InfCareHIV cohort who started a treatment combination with any of the most commonly used 3^rd^ agents from the non-nucleoside reverse transcriptase inhibitor class (NNRTI), the protease inhibitor class (PI) and the integrase inhibitor class (INI) between 2009 to 2014.

Methods {#sec006}
=======

Cohort {#sec007}
------

InfCareHIV has been set-up as a decision support tool in daily clinical care and is also used as a consultation tool for HIV treating physicians, for research purposes and serves also as the National Quality Registry InfCareHIV in Sweden. InfCareHIV was first implemented at Karolinska University Hospital in Stockholm and at Sahlgrenska University Hospital in Gothenburg in 2003 and as of 2009 InfCareHIV was rolled out in all 30 HIV-clinics throughout the country. Patient data, biomarkers, laboratory test results, co-infections and HIV treatments are entered into InfCareHIV, allowing for national follow-up of the care of the Swedish HIV cohort with an estimated coverage of \>99% of all patients diagnosed with HIV infection. All HIV patients are actively seen 2--4 times every year and data entry into InfCareHIV is done in conjunction with each clinical visit. For this study, anonymized data was extracted from the existing national registry InfCareHIV.

Naïve or treatment-experienced adult patients who started a new therapy defined as a new 3^rd^ agent between January 1^st^ 2009 and December 31^st^ 2014 were included in the study and followed until the 3^rd^ agent discontinuation, loss to follow up/death or end of study period. Third agents constitute all ARV's that are not N\[t\]RTIs and that are added to a backbone regimen of usually two N\[t\]RTIs.

The integrase inhibitor dolutegravir, launched in Sweden in February 2014, was not included as follow-up time was too short. Patients with HIV-2 infection or under the age 18 were excluded from the analyses.

Exposure status {#sec008}
---------------

Included in the treatment-naive analysis were patients starting their first treatment regimen ever during the study period 2009--2014.

Included in the treatment-experienced analysis were patients with a prior ARV treatment and starting a new treatment including a 3^rd^ agent during 2009--2014. Patients with a prior treatment regimen only including N\[t\]RTIs and then starting their first regimen including a 3^rd^ agent during the study period were denoted first line treatment experienced patients and patients with one prior 3^rd^ agent containing regimen starting the second 3^rd^ agent during the study period were denoted 2^nd^ line treatment experienced patients. Patients switching 3^rd^ agents during the study period could contribute to several observation periods.

If a 3^rd^ agent was added without withdrawing the previous 3^rd^ agent the patient was still considered on original 3^rd^ agent and a new follow up period was started for the add on 3^rd^ agent. Switch from triple therapy (N\[t\]RTIs + 3^rd^ agent) to a dual or mono therapy by reducing the N\[t\]RTIs was still considered the same line of therapy as long as the 3^rd^ agent remained the same. A switch from ritonavir-boosted ATV to non-boosted ATV was considered the same line of therapy. All drugs were dosed according to label; lopinavir and raltegravir twice daily, darunavir once daily in treatment naive patients and once or twice daily in treatment-experienced patients. Treatment interruptions of 30 days or less and then continuing with the same 3^rd^ agent were handled as one treatment sequence in the treatment retention analysis. Treatment interruptions of more than 30 days were considered as a treatment discontinuation.

Analysis {#sec009}
--------

Descriptive statistics were used to calculate number of patients on treatment. Multivariate Cox proportional hazards models were used to estimate hazard ratios for treatment discontinuation. The most commonly prescribed 3^rd^ agent was used as a reference. For treatment-naïve patients, it was efavirenz and for treatment-experienced patients, it was darunavir. Variables collected in the InfCareHIV cohort and with a known or theoretical relationship to either the exposure or outcome, or both, were included in the analysis to assess for potential confounding biases: age, gender, mode of transmission, region of birth, CDC class, hepatitis status, year of treatment start, baseline CD4, baseline viral load, backbone treatment used, and for treatment experienced patients also line of therapy and years since start of first ARV treatment. Early treatment discontinuation refers to covariates or 3^rd^ agents with a significantly higher risk (hazard ratio) for treatment discontinuation in the multivariate Cox regression model compared to the reference. For region of birth we used a modified UNAIDS regional classification dividing the regions in 4 geographical areas; 1. Sweden, 2. Western Europe, USA, Canada, Israel, Middle East, North Africa, 3. Africa East, South, West, Central, 4. Eastern Europe, Asia, Pacific, Caribbean, and Latin America. If a CD4 count or viral load was missing at treatment start laboratory results from the first week of therapy or from the preceding 6 months were used as baseline values.

Analyses are stratified by treatment-naive and treatment-experienced individuals. Only treatments with more than 100 observations of initiation or change of a 3^rd^ agent in treatment-naive or treatment-experienced patients were included in the analyses. Adjusted and unadjusted hazard ratios (HR) with corresponding 95% confidence intervals (CI) are shown. Treatment discontinuation rates were calculated (1-Kaplan Meier \*100%) overall and per therapy for both naïve and experienced patient populations at 90 days, one year, two years and three years after start of treatment. Data were analyzed using SAS version 9.2.

Ethical considerations {#sec010}
----------------------

The InfCareHIV registry has ethical approval for studies with retrospective analyses on de-identified patient data (Regional Ethical Review Board, University of Gothenburg Dnr 532--11).

Results {#sec011}
=======

After exclusions a total of 4724 patients and 7142 observations were included in the analyses. Among treatment-naïve, 2537 patients corresponding to 2583 observations and among treatment-experienced, 2991 patients corresponding to 4552 observations were included. 46 treatment-naive patients started a regimen including two 3^rd^ agents. The 3^rd^ agents initiated by more than 100 treatment naive patients during the study period and thereby included in the analysis were efavirenz, rilpivirine, lopinavir, atazanavir, darunavir and raltegravir. The same antiretroviral drugs were included in the analyses of treatment-experienced patients with the addition of etravirine. The mean 3^rd^ agent treatment observation time for treatment naive and treatment experienced patients were 28.1 and 28.2 months, respectively.

Baseline characteristics {#sec012}
------------------------

### Treatment-naive patients {#sec013}

In treatment-naïve 2537 patients initiating cART with a 3^rd^ agent were included in the study during the six year study period 2009--2014. They were predominately male (63%) and 81% were less than 50 years old at treatment start. Transmission route was heterosexual contact in 51%, men who have sex with men (MSM) in 31%, intravenous drug use (IVDU) in 6% and other/unknown in 8%. Data on transmission route was missing in 3% of cases. Thirty-six percent of the patients had African origin, 34% were from Sweden, 16% Asian/Eastern Euroupe and 14% were from Western Europe/North America. In eight percent of the observations the patient had a history of AIDS diagnosis at start of their first ART. Efavirenz was the most commonly used 3^rd^ agent (n = 1096) followed by darunavir (n = 504), atazanavir (n = 386), lopinavir (n = 292), rilpivirine (n = 156) and raltegravir (n = 149). There were differences in the use of the different ARVs in relation to patient characteristics. This was most clearly seen with rilpivirine that was rarely used in patients with high baseline viral load or low CD4 cell counts; only 3% of the rilpivirine patients had a baseline viral load \>100 000 HIV-RNA copies/mL, 3% had a CD4 cell count \<200/μL and none of the patients receiving rilpivirine as treatment-naïve had a history of AIDS diagnosis at treatment start. A higher proportion of the patients starting darunavir or lopinavir had a CD4 cell count below 200/μL, and together with raltegravir a higher proportion also had an AIDS diagnosis at start of treatment. Patients starting darunavir or raltegravir more often had a viral load \>100 000 copies/mL. Lopinavir and atazanavir were significantly more often used in women. A full description of baseline characteristics for treatment-naive patients can be found in [Table 1](#pone.0171227.t001){ref-type="table"}.

10.1371/journal.pone.0171227.t001

###### Baseline characteristics for treatment-naive patients.

![](pone.0171227.t001){#pone.0171227.t001g}

  Covariate                                         Value                                                            Efavirenz (n = 1096)   Rilpivirine (n = 156)   Lopinavir (n = 292)   Atazanavir (n = 386)   Darunavir (n = 504)   Raltegravir (n = 149)   Total (n = 2583)
  ------------------------------------------------- ---------------------------------------------------------------- ---------------------- ----------------------- --------------------- ---------------------- --------------------- ----------------------- -------------------
  Age                                               Age \<50                                                         878 (80.1%)            133 (85.3%)             258 (88.4%)           317 (82.1%)            401 (79.6%)           114 (76.5%)             2101 (81.3%)
                                                    Age ≥50                                                          218 (19.9%)            23 (14.7%)              34 (11.6%)            69 (17.9%)             102 (20.2%)           35 (23.5%)              481 (18.6%)
                                                    Missing                                                                                                                                                      1 (0.2%)                                      1 (0.0%)
  NRTI Backbone                                     No Backbone                                                      4 (0.4%)               1 (0.6%)                3 (1.0%)              3 (0.8%)               36 (7.1%)             27 (18.1%)              74 (2.9%)
                                                    ABC/3TC                                                          183 (16.7%)            4 (2.6%)                69 (23.6%)            162 (42.0%)            166 (32.9%)           14 (9.4%)               598 (23.2%)
                                                    TDF/FTC                                                          863 (78.7%)            151 (96.8%)             102 (34.9%)           205 (53.1%)            298 (59.1%)           102 (68.5%)             1721 (66.6%)
                                                    Other                                                            46 (4.2%)                                      118 (40.4%)           16 (4.1%)              4 (0.8%)              6 (4.0%)                190 (7.4%)
  CD4 cell count at baseline                        ≤200                                                             316 (28.8%)            5 (3.2%)                104 (35.6%)           110 (28.5%)            175 (34.7%)           43 (28.9%)              753 (29.2%)
                                                    201--350                                                         394 (35.9%)            39 (25.0%)              90 (30.8%)            152 (39.4%)            146 (29.0%)           28 (18.8%)              849 (32.9%)
                                                    351--500                                                         207 (18.9%)            58 (37.2%)              47 (16.1%)            70 (18.1%)             106 (21.0%)           45 (30.2%)              533 (20.6%)
                                                    \>500                                                            88 (8.0%)              47 (30.1%)              31 (10.6%)            37 (9.6%)              50 (9.9%)             24 (16.1%)              277 (10.7%)
                                                    Missing                                                          91 (8.3%)              7 (4.5%)                20 (6.8%)             17 (4.4%)              27 (5.4%)             9 (6.0%)                171 (6.6%)
  CDC Class                                         C/AIDS                                                           75 (6.8%)                                      42 (14.4%)            27 (7.0%)              53 (10.5%)            21 (14.1%)              218 (8.4%)
                                                    Non-C (i.e. A or B)                                              1021 (93.2%)           156 (100.0%)            250 (85.6%)           359 (93.0%)            451 (89.5%)           128 (85.9%)             2365 (91.6%)
  Region of birth                                   Sweden                                                           357 (32.6%)            62 (39.7%)              57 (19.5%)            125 (32.4%)            201 (39.9%)           64 (43.0%)              866 (33.5%)
                                                    Western Europe, USA, Israel, Canada, North Africa, Middle East   152 (13.9%)            38 (24.4%)              18 (6.2%)             46 (11.9%)             71 (14.1%)            33 (22.1%)              358 (13.9%)
                                                    Africa (East, South, West and Central)                           405 (37.0%)            28 (17.9%)              157 (53.8%)           147 (38.1%)            147 (29.2%)           36 (24.2%)              920 (35.6%)
                                                    Eastern Europe, Asia, Pacific, Caribbean, Latin America          168 (15.3%)            25 (16.0%)              57 (19.5%)            63 (16.3%)             74 (14.7%)            15 (10.1%)              402 (15.6%)
                                                    Missing                                                          14 (1.3%)              3 (1.9%)                3 (1.0%)              5 (1.3%)               11 (2.2%)             1 (0.7%)                37 (1.4%)
  Gender                                            Male                                                             779 (71.1%)            120 (76.9%)             90 (30.8%)            202 (52.3%)            334 (66.3%)           105 (70.5%)             1630 (63.1%)
                                                    Female                                                           317 (28.9%)            36 (23.1%)              202 (69.2%)           184 (47.7%)            170 (33.7%)           44 (29.5%)              953 (36.9%)
                                                                                                                                                                                                                                                                
  Hepatitis status                                  Negative                                                         1066 (97.3%)           151 (96.8%)             280 (95.9%)           360 (93.3%)            477 (94.6%)           145 (97.3%)             2479 (96.0%)
                                                    Hep B seropositive                                               14 (1.3%)              2 (1.3%)                3 (1.0%)              4 (1.0%)               6 (1.2%)              1 (0.7%)                30 (1.2%)
                                                    Hep C seropositive                                               16 (1.5%)              3 (1.9%)                8 (2.7%)              22 (5.7%)              19 (3.8%)             3 (2.0%)                71 (2.7%)
                                                    Hep B+C seropositive                                                                                            1 (0.3%)                                     2 (0.4%)                                      3 (0.1%)
  Transmission Route                                Heterosexual                                                     572 (52.2%)            52 (33.3%)              193 (66.1%)           219 (56.7%)            229 (45.4%)           52 (34.9%)              1317 (51.0%)
                                                    MSM                                                              353 (32.2%)            90 (57.7%)              27 (9.2%)             83 (21.5%)             176 (34.9%)           81 (54.4%)              810 (31.4%)
                                                    IVDU                                                             39 (3.6%)              5 (3.2%)                23 (7.9%)             35 (9.1%)              44 (8.7%)             5 (3.4%)                151 (5.8%)
                                                    Other/unknown                                                    100 (9.1%)             4 (2.6%)                42 (14.4%)            38 (9.8%)              26 (5.2%)             9 (6.0%)                219 (8.5%)
                                                    Missing                                                          32 (2.9%)              5 (3.2%)                7 (2.4%)              11 (2.8%)              29 (5.8%)             2 (1.3%)                86 (3.3%)
  Treatment Start Year                              2009--2010                                                       449 (41.0%)            4 (2.6%)                202 (69.2%)           197 (51.0%)            53 (10.5%)            28 (18.8%)              933 (36.1%)
                                                    2011--2012                                                       384 (35.0%)            38 (24.4%)              72 (24.7%)            116 (30.1%)            228 (45.2%)           52 (34.9%)              890 (34.5%)
                                                    2013--2014                                                       263 (24.0%)            114 (73.1%)             18 (6.2%)             73 (18.9%)             223 (44.2%)           69 (46.3%)              760 (29.4%)
  Baseline Viral Load                               \<50                                                             19 (1.7%)              4 (2.6%)                13 (4.5%)             7 (1.8%)               9 (1.8%)              5 (3.4%)                57 (2.2%)
                                                    51--1,000                                                        48 (4.4%)              14 (9.0%)               21 (7.2%)             18 (4.7%)              22 (4.4%)             7 (4.7%)                130 (5.0%)
                                                    1,001--10,000                                                    143 (13.0%)            62 (39.7%)              54 (18.5%)            62 (16.1%)             70 (13.9%)            16 (10.7%)              407 (15.8%)
                                                    10,001--100,000                                                  407 (37.1%)            65 (41.7%)              105 (36.0%)           150 (38.9%)            191 (37.9%)           60 (40.3%)              978 (37.9%)
                                                    \>100,000                                                        359 (32.8%)            4 (2.6%)                73 (25.0%)            120 (31.1%)            186 (36.9%)           51 (34.2%)              793 (30.7%)
                                                    Missing                                                          120 (10.9%)            7 (4.5%)                26 (8.9%)             29 (7.5%)              26 (5.2%)             10 (6.7%)               218 (8.4%)
  Age (median, p25-p75)                                                                                              39 (32--47)            37 (31--46)             35 (29--41)           37 (31--45)            39 (32--48)           40 (33--48)             38 (31--47)
  Year Start 1st Line Treatment (median, p25-p75)                                                                    2011 (2010--2012)      2013 (2012--2013)       2010 (2009--2011)     2010 (2010--2012)      2012 (2011--2013)     2012 (2011--2014)       2011 (2010--2013)

### Treatment-experienced patients {#sec014}

During the 6 year observation period 2991 treatment-experienced patients started 4552 episodes of treatments with a 3^rd^ agent. At treatment start 58% were male. Transmission route and country of origin were similar to treatment-naive patients. 18% had a history of AIDS at start of treatment and 13% had a CD4 cell count below 200/μL. 57% of the treatments started in a patient with a viral load \<50 HIV-RNA copies/mL. In 37% of the observations the patients started a 2nd line treatment, in 23% a 3^rd^ line and in 39% the patient started treatment line 4 or higher. Darunavir was the mostly used ART with 1285 observed treatments followed by 806 observed treatments with atazanavir. A full description of baseline characteristics for treatment-experienced patient can be found in [Table 2](#pone.0171227.t002){ref-type="table"}.

10.1371/journal.pone.0171227.t002

###### Baseline characteristics for treatment-experienced patients.

![](pone.0171227.t002){#pone.0171227.t002g}

  Covariate                                   Value                                                            Efavirenz (n = 694)   Etravirine (n = 262)   Rilpivirine (n = 592)   Lopinavir (n = 291)   Atazanavir (n = 806)   Darunavir (n = 1285)   Raltegravir (n = 622)   Total (n = 4552)
  ------------------------------------------- ---------------------------------------------------------------- --------------------- ---------------------- ----------------------- --------------------- ---------------------- ---------------------- ----------------------- -------------------
  Age                                         Age \<50                                                         536 (77.2%)           164 (62.6%)            404 (68.2%)             212 (72.9%)           602 (74.7%)            868 (67.5%)            358 (57.6%)             3144 (69.1%)
                                              Age ≥50                                                          158 (22.8%)           98 (37.4%)             188 (31.8%)             77 (26.5%)            204 (25.3%)            416 (32.4%)            262 (42.1%)             1403 (30.8%)
                                              Missing                                                                                                                               2 (0.7%)                                     1 (0.1%)               2 (0.3%)                5 (0.1%)
  NRTI Backbone                               No Backbone                                                      4 (0.6%)              77 (29.4%)             8 (1.4%)                18 (6.2%)             8 (1.0%)               137 (10.7%)            104 (16.7%)             356 (7.8%)
                                              ABC/3TC                                                          128 (18.4%)           38 (14.5%)             115 (19.4%)             95 (32.6%)            379 (47.0%)            447 (34.8%)            174 (28.0%)             1376 (30.2%)
                                              TDF/FTC                                                          530 (76.4%)           106 (40.5%)            461 (77.9%)             107 (36.8%)           385 (47.8%)            601 (46.8%)            273 (43.9%)             2463 (54.1%)
                                              Other                                                            32 (4.6%)             41 (15.6%)             8 (1.4%)                71 (24.4%)            34 (4.2%)              100 (7.8%)             71 (11.4%)              357 (7.8%)
  CD4 cell count at baseline                  ≤200                                                             73 (10.5%)            34 (13.0%)             25 (4.2%)               54 (18.6%)            107 (13.3%)            220 (17.1%)            93 (15.0%)              606 (13.3%)
                                              201--350                                                         153 (22.0%)           48 (18.3%)             70 (11.8%)              87 (29.9%)            216 (26.8%)            268 (20.9%)            102 (16.4%)             944 (20.7%)
                                              351--500                                                         165 (23.8%)           61 (23.3%)             123 (20.8%)             56 (19.2%)            188 (23.3%)            283 (22.0%)            116 (18.6%)             992 (21.8%)
                                              \>500                                                            247 (35.6%)           94 (35.9%)             290 (49.0%)             68 (23.4%)            236 (29.3%)            421 (32.8%)            250 (40.2%)             1606 (35.3%)
                                              Missing                                                          56 (8.1%)             25 (9.5%)              84 (14.2%)              26 (8.9%)             59 (7.3%)              93 (7.2%)              61 (9.8%)               404 (8.9%)
  CDC Class                                   C/AIDS                                                           105 (15.1%)           71 (27.1%)             79 (13.3%)              60 (20.6%)            124 (15.4%)            238 (18.5%)            146 (23.5%)             823 (18.1%)
                                              Non-C (i.e. A or B)                                              589 (84.9%)           191 (72.9%)            513 (86.7%)             231 (79.4%)           682 (84.6%)            1047 (81.5%)           476 (76.5%)             3729 (81.9%)
  Region of birth                             Sweden                                                           222 (32.0%)           140 (53.4%)            260 (43.9%)             102 (35.1%)           293 (36.4%)            496 (38.6%)            303 (48.7%)             1816 (39.9%)
                                              Western Europe, USA, Israel, Canada, North Africa, Middle East   78 (11.2%)            43 (16.4%)             104 (17.6%)             20 (6.9%)             80 (9.9%)              161 (12.5%)            90 (14.5%)              576 (12.7%)
                                              Africa (East, South, West and Central)                           284 (40.9%)           58 (22.1%)             151 (25.5%)             126 (43.3%)           323 (40.1%)            485 (37.7%)            171 (27.5%)             1598 (35.1%)
                                              Eastern Europe, Asia, Pacific, Caribbean, Latin America          102 (14.7%)           21 (8.0%)              66 (11.1%)              41 (14.1%)            106 (13.2%)            133 (10.4%)            52 (8.4%)               521 (11.4%)
                                              Missing                                                          8 (1.2%)                                     11 (1.9%)               2 (0.7%)              4 (0.5%)               10 (0.8%)              6 (1.0%)                41 (0.9%)
  Gender                                      Male                                                             365 (52.6%)           195 (74.4%)            398 (67.2%)             129 (44.3%)           404 (50.1%)            753 (58.6%)            407 (65.4%)             2651 (58.2%)
                                              Female                                                           329 (47.4%)           67 (25.6%)             194 (32.8%)             162 (55.7%)           402 (49.9%)            532 (41.4%)            215 (34.6%)             1901 (41.8%)
                                                                                                                                                                                                                                                                                 
  Hepatitis status                            Negative                                                         651 (93.8%)           251 (95.8%)            554 (93.6%)             271 (93.1%)           733 (90.9%)            1197 (93.2%)           584 (93.9%)             4241 (93.2%)
                                              Hep B seropositive                                               18 (2.6%)             5 (1.9%)               13 (2.2%)               1 (0.3%)              10 (1.2%)              27 (2.1%)              12 (1.9%)               86 (1.9%)
                                              Hep C seropositive                                               23 (3.3%)             6 (2.3%)               23 (3.9%)               18 (6.2%)             61 (7.6%)              56 (4.4%)              26 (4.2%)               213 (4.7%)
                                              Hep B+C seropositive                                             2 (0.3%)                                     2 (0.3%)                1 (0.3%)              2 (0.2%)               5 (0.4%)                                       12 (0.3%)
  Transmission Route                          Heterosexual                                                     416 (59.9%)           96 (36.6%)             263 (44.4%)             181 (62.2%)           464 (57.6%)            669 (52.1%)            268 (43.1%)             2357 (51.8%)
                                              MSM                                                              186 (26.8%)           142 (54.2%)            272 (45.9%)             44 (15.1%)            168 (20.8%)            366 (28.5%)            276 (44.4%)             1454 (31.9%)
                                              IVDU                                                             28 (4.0%)             10 (3.8%)              17 (2.9%)               38 (13.1%)            106 (13.2%)            129 (10.0%)            30 (4.8%)               358 (7.9%)
                                              Other/unknown                                                    60 (8.6%)             13 (5.0%)              36 (6.1%)               23 (7.9%)             62 (7.7%)              114 (8.9%)             45 (7.2%)               353 (7.8%)
                                              Missing                                                          4 (0.6%)              1 (0.4%)               4 (0.7%)                5 (1.7%)              6 (0.7%)               7 (0.5%)               3 (0.5%)                30 (0.7%)
  Treatment Start Year                        2009--2010                                                       377 (54.3%)           121 (46.2%)                                    194 (66.7%)           424 (52.6%)            327 (25.4%)            211 (33.9%)             1654 (36.3%)
                                              2011--2012                                                       218 (31.4%)           80 (30.5%)             202 (34.1%)             74 (25.4%)            266 (33.0%)            545 (42.4%)            232 (37.3%)             1617 (35.5%)
                                              2013--2014                                                       99 (14.3%)            61 (23.3%)             390 (65.9%)             23 (7.9%)             116 (14.4%)            413 (32.1%)            179 (28.8%)             1281 (28.1%)
  Line of Therapy                             1[\*](#t002fn001){ref-type="table-fn"}                           30 (4.3%)             1 (0.4%)               5 (0.8%)                5 (1.7%)              13 (1.6%)              8 (0.6%)               4 (0.6%)                66 (1.4%)
                                              2                                                                352 (50.7%)           31 (11.8%)             261 (44.1%)             119 (40.9%)           336 (41.7%)            391 (30.4%)            157 (25.2%)             1647 (36.2%)
                                              3                                                                164 (23.6%)           43 (16.4%)             130 (22.0%)             75 (25.8%)            204 (25.3%)            311 (24.2%)            130 (20.9%)             1057 (23.2%)
                                              4+                                                               148 (21.3%)           187 (71.4%)            196 (33.1%)             92 (31.6%)            253 (31.4%)            575 (44.7%)            331 (53.2%)             1782 (39.1%)
  Baseline Viral Load                         \<50                                                             433 (62.4%)           136 (51.9%)            515 (87.0%)             98 (33.7%)            424 (52.6%)            649 (50.5%)            358 (57.6%)             2613 (57.4%)
                                              51--1,000                                                        65 (9.4%)             59 (22.5%)             31 (5.2%)               49 (16.8%)            98 (12.2%)             236 (18.4%)            120 (19.3%)             658 (14.5%)
                                              1,001--10,000                                                    55 (7.9%)             18 (6.9%)              18 (3.0%)               36 (12.4%)            68 (8.4%)              102 (7.9%)             41 (6.6%)               338 (7.4%)
                                              10,001--100,000                                                  76 (11.0%)            29 (11.1%)             13 (2.2%)               53 (18.2%)            116 (14.4%)            165 (12.8%)            60 (9.6%)               512 (11.2%)
                                              \>100,000                                                        34 (4.9%)             16 (6.1%)              3 (0.5%)                37 (12.7%)            65 (8.1%)              110 (8.6%)             26 (4.2%)               291 (6.4%)
                                              Missing                                                          31 (4.5%)             4 (1.5%)               12 (2.0%)               18 (6.2%)             35 (4.3%)              23 (1.8%)              17 (2.7%)               140 (3.1%)
  Years Since Start of first ART              0--2 years                                                       278 (40.1%)           56 (21.4%)             190 (32.1%)             108 (37.1%)           289 (35.9%)            327 (25.4%)            165 (26.5%)             1413 (31.0%)
                                              3--5 years                                                       106 (15.3%)           23 (8.8%)              101 (17.1%)             48 (16.5%)            122 (15.1%)            170 (13.2%)            53 (8.5%)               623 (13.7%)
                                              5+ years                                                         310 (44.7%)           183 (69.8%)            301 (50.8%)             135 (46.4%)           395 (49.0%)            788 (61.3%)            404 (65.0%)             2516 (55.3%)
  Age (median, p25-p75)                                                                                        41 (34--49)           47 (41--56)            44 (37--53)             41 (34--50)           42 (35--50)            44 (37--52)            47 (40--56)             44 (36--52)
  Year Start of first ART (median, p25-p75)                                                                    2006 (2001--2009)     2000 (1997--2007)      2008 (2002--2011)       2006 (2001--2008)     2006 (2002--2009)      2005 (1998--2009)      2003 (1998--2009)       2005 (1999--2009)

\*Includes patients with a prior treatment episode including only N\[t\]RTIs and starting their first treatment including a 3^rd^ agent during the study period 2009--2014

### Overall treatment discontinuation rates {#sec015}

Ten percent of treatment naive patients had discontinued the 3^rd^ agent within 90 days from start of treatment. After one year 24% had discontinued, after two years 33% and after three years 42%. Among treatment-experienced patients overall discontinuation rates were very similar; 11% after 90 days, 24% after one year, 34% after two years and 41% after three years. Discontinuation rates varied widely between drugs with the highest discontinuation rates seen with lopinavir; approximately half of the patients, both in treatment-naïve and treatment-experienced patients had discontinued lopinavir within one year from treatment start. The lowest discontinuation rate was seen in patients treated with rilpivirine where only 7% and 12% of treatment-naive and treatment-experienced patients respectively discontinued within one year. Discontinuation rates for all drugs can be found in [Table 3](#pone.0171227.t003){ref-type="table"}.

10.1371/journal.pone.0171227.t003

###### Discontinuation rates (1-KM\*100%) for treatment-naive and treatment-experienced patient populations.

![](pone.0171227.t003){#pone.0171227.t003g}

  Patient Population   Treatment     90 days            1 year             2 years            3 years
  -------------------- ------------- ------------------ ------------------ ------------------ ------------------
  Naive                Efavirenz     0.10 (0.09;0.12)   0.21 (0.19;0.24)   0.29 (0.26;0.32)   0.35 (0.32;0.38)
                       Rilpivirine   0.04 (0.02;0.08)   0.07 (0.04;0.13)   0.11 (0.07;0.18)   0.17 (0.10;0.28)
                       Lopinavir     0.16 (0.13;0.21)   0.52 (0.46;0.58)   0.69 (0.64;0.74)   0.79 (0.74;0.83)
                       Atazanavir    0.10 (0.07;0.14)   0.22 (0.18;0.26)   0.29 (0.25;0.34)   0.36 (0.31;0.41)
                       Darunavir     0.07 (0.05;0.09)   0.18 (0.15;0.22)   0.28 (0.24;0.33)   0.41 (0.36;0.47)
                       Raltegravir   0.13 (0.09;0.20)   0.33 (0.26;0.42)   0.43 (0.35;0.53)   0.59 (0.50;0.69)
                       Total         0.10 (0.09;0.11)   0.24 (0.22;0.26)   0.33 (0.32;0.35)   0.42 (0.40;0.44)
  Experienced          Efavirenz     0.16 (0.13;0.19)   0.30 (0.27;0.34)   0.38 (0.35;0.42)   0.44 (0.40;0.48)
                       Etravirine    0.17 (0.13;0.22)   0.29 (0.24;0.35)   0.41 (0.35;0.47)   0.47 (0.40;0.53)
                       Rilpivirine   0.06 (0.04;0.08)   0.12 (0.09;0.15)   0.16 (0.13;0.20)   0.22 (0.18;0.28)
                       Lopinavir     0.20 (0.16;0.25)   0.50 (0.44;0.56)   0.68 (0.63;0.74)   0.76 (0.71;0.81)
                       Atazanavir    0.10 (0.08;0.12)   0.25 (0.22;0.28)   0.38 (0.34;0.41)   0.45 (0.42;0.49)
                       Darunavir     0.07 (0.06;0.09)   0.18 (0.16;0.20)   0.28 (0.25;0.30)   0.33 (0.30;0.36)
                       Raltegravir   0.11 (0.08;0.13)   0.26 (0.23;0.30)   0.34 (0.30;0.38)   0.41 (0.37;0.46)
                       Total         0.11 (0.10;0.12)   0.24 (0.23;0.25)   0.34 (0.33;0.36)   0.41 (0.39;0.42)

Analysis of treatment duration {#sec016}
------------------------------

### Treatment-naïve patients {#sec017}

Among treatment-naïve patients the 3^rd^ agents had different discontinuation rates. In comparison with efavirenz, patients on rilpivirine were least likely to discontinue treatment (adjusted HR 0.33; 95% CI 0.20--0.54, p\<0.001), while patients on lopinavir were most likely to discontinue treatment (adjusted HR 2.80; 95% CI 2.30--3.40, p\<0.001), see [Fig 1A](#pone.0171227.g001){ref-type="fig"}. Also raltegravir was associated with early treatment discontinuation (adjusted HR 1.47; 95% CI 1.12--1.92, p = 0.005). The adjusted HR for atazanavir and darunavir were not significantly different from efavirenz. Hazard ratios for treatment-naive patients can be seen in [Fig 1](#pone.0171227.g001){ref-type="fig"}.

![Risk for treatment discontinuation in treatment-naive patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).](pone.0171227.g001){#pone.0171227.g001}

Patients with an AIDS diagnosis at treatment start had a significantly higher risk for early treatment discontinuation than non-AIDS patients. Other co-variables independently associated with early treatment discontinuation in the multivariate adjusted model were N\[t\]RTI backbone other than ABC/3TCor TAF/FTC and treatment start year 2011 or later compared to treatment start 2009--2010.

When transmission route was known to be heterosexual, patients were less likely to discontinue 3^rd^ agent treatment than MSM (adjusted HR 0.67; 95% CI 0.56--0.80, p\<0.001). Age, gender, hepatitis status, region of birth, CD4 cell count \<200/μL and viral load \>100.000 HIV-RNA copies/mL at treatment start were not correlated with treatment discontinuation ([Table 4](#pone.0171227.t004){ref-type="table"}).

10.1371/journal.pone.0171227.t004

###### Hazard Ratios from univariate and multivariate Cox regression models for treatment-naive patients.

![](pone.0171227.t004){#pone.0171227.t004g}

  Covariate                    Value                                                            Distinct Patients (n)   Observations (n)   HR (95% CI) univariate model   P-value   HR (95% CI) multivariate model[\*](#t004fn001){ref-type="table-fn"}   P-value
  ---------------------------- ---------------------------------------------------------------- ----------------------- ------------------ ------------------------------ --------- --------------------------------------------------------------------- ---------
  Age                          Age \<50                                                         2068                    2101               Reference                                Reference                                                              
                               Age ≥50                                                          472                     481                0.88 (0.75;1.03)               0.111     0.95 (0.80;1.12)                                                      0.548
                               Missing                                                          1                       1                  10.58 (1.50;74.82)             0.018     23.78 (3.21;175.91)                                                   0.002
  N\[t\]RTI Backbone           No Backbone                                                      50                      74                 1.57 (1.16;2.13)               0.004     1.24 (0.89;1.73)                                                      0.210
                               ABC/3TC                                                          597                     598                1.16 (1.00;1.35)               0.045     1.06 (0.91;1.25)                                                      0.439
                               TDF/FTC                                                          1708                    1721               Reference                                Reference                                                              
                               Other                                                            186                     190                3.01 (2.51;3.61)               \<0.001   2.16 (1.72;2.71)                                                      \<0.001
  CD4 cell count at Baseline   ≤200                                                             736                     753                0.90 (0.73;1.12)               0.358     0.83 (0.65;1.05)                                                      0.127
                               201--350                                                         840                     849                0.73 (0.59;0.90)               0.004     0.77 (0.62;0.97)                                                      0.025
                               351--500                                                         524                     533                0.86 (0.68;1.08)               0.187     0.87 (0.69;1.10)                                                      0.260
                               \>500                                                            272                     277                Reference                                Reference                                                              
                               Missing                                                          169                     171                0.66 (0.49;0.90)               0.008     0.60 (0.39;0.94)                                                      0.024
  CDC Class                    C/AIDS                                                           207                     218                1.56 (1.29;1.88)               \<0.001   1.42 (1.15;1.76)                                                      0.001
                               Non-C (i.e. A or B)                                              2334                    2365               Reference                                Reference                                                              
  Region of birth              Sweden                                                           849                     866                Reference                                Reference                                                              
                               Western Europe, USA, Israel, Canada, North Africa, Middle East   353                     358                0.98 (0.81;1.19)               0.861     1.00 (0.82;1.21)                                                      0.970
                               Africa (East, South, West and Central)                           901                     920                1.06 (0.92;1.22)               0.436     1.08 (0.90;1.30)                                                      0.409
                               Eastern Europe, Asia, Pacific, Caribbean, Latin America          401                     402                0.91 (0.75;1.10)               0.316     0.85 (0.69;1.05)                                                      0.141
                               Missing                                                          37                      37                 0.65 (0.35;1.22)               0.182     0.83 (0.43;1.62)                                                      0.587
  Gender                       Male                                                             1608                    1630               Reference                                Reference                                                              
                               Female                                                           933                     953                1.13 (1.00;1.27)               0.060     1.02 (0.86;1.21)                                                      0.809
  Hepatitis Status             Negative                                                         2438                    2479               Reference                                Reference                                                              
                               Hep B seropositive                                               30                      30                 0.84 (0.46;1.52)               0.565     0.88 (0.49;1.61)                                                      0.688
                               Hep C seropositive                                               70                      71                 1.16 (0.83;1.61)               0.381     1.21 (0.84;1.73)                                                      0.314
                               Hep B+C seropositive                                             3                       3                  2.07 (0.52;8.27)               0.305     1.75 (0.43;7.17)                                                      0.434
  Transmission Route           Heterosexual                                                     1293                    1317               0.86 (0.75;0.99)               0.029     0.67 (0.56;0.80)                                                      \<0.001
                               MSM                                                              796                     810                Reference                                Reference                                                              
                               IVDU                                                             151                     151                0.95 (0.73;1.23)               0.703     0.78 (0.58;1.04)                                                      0.094
                               Other/unknown                                                    215                     219                1.15 (0.92;1.43)               0.211     0.82 (0.64;1.06)                                                      0.139
                               Missing                                                          86                      86                 0.61 (0.39;0.93)               0.023     0.56 (0.35;0.89)                                                      0.015
  Treatment Start Year         2009--2010                                                       926                     933                Reference                                Reference                                                              
                               2011--2012                                                       865                     890                0.98 (0.85;1.12)               0.765     1.16 (1.00;1.35)                                                      0.048
                               2013--2014                                                       750                     760                0.84 (0.70;1.00)               0.049     1.26 (1.03;1.54)                                                      0.023
  Baseline Viral Load          \<50                                                             54                      57                 Reference                                Reference                                                              
                               51--1,000                                                        128                     130                0.83 (0.50;1.37)               0.458     1.09 (0.65;1.81)                                                      0.749
                               1,001--10,000                                                    405                     407                0.86 (0.55;1.34)               0.493     1.15 (0.73;1.82)                                                      0.536
                               10,001--100,000                                                  957                     978                0.83 (0.54;1.28)               0.399     1.11 (0.72;1.73)                                                      0.639
                               \>100,000                                                        781                     793                1.00 (0.65;1.53)               0.986     1.33 (0.85;2.08)                                                      0.214
                               Missing                                                          216                     218                0.75 (0.47;1.20)               0.236     1.06 (0.62;1.82)                                                      0.821
  3rd Agent                    Efavirenz                                                        1096                    1096               Reference                                Reference                                                              
                               Rilpivirine                                                      156                     156                0.38 (0.24;0.61)               \<0.001   0.33 (0.20;0.54)                                                      \<0.001
                               Lopinavir                                                        292                     292                3.23 (2.76;3.79)               \<0.001   2.80 (2.30;3.40)                                                      \<0.001
                               Atazanavir                                                       386                     386                1.08 (0.90;1.29)               0.416     1.06 (0.88;1.29)                                                      0.528
                               Darunavir                                                        504                     504                1.07 (0.89;1.28)               0.467     0.94 (0.77;1.14)                                                      0.516
                               Raltegravir                                                      149                     149                1.85 (1.45;2.37)               \<0.001   1.47 (1.12;1.92)                                                      0.005

\* Adjustments made for treatment, age, gender, region of birth, CD4 count at baseline, viral load at baseline, CDC class, route of infection, year of initiation treatment, hepatitis status, N\[t\]RTI backbone treatment.

### Treatment-experienced patients {#sec018}

Also among treatment-experienced patients, the use of different 3^rd^ agents showed significant different correlations to treatment discontinuation. With darunavir as the reference, patients on rilpivirine had significantly lower discontinuation rates (adjusted HR 0.66; 95% CI 0.52--0.83, p\<0.001) and all other drugs had significantly higher risk for discontinuation in the multivariate adjusted analyses; efavirenz (HR 1.86; 95% CI 1.59--2.17, p\<0.001), etravirine (HR 1.61; 95% CI 1.31--1.98, p\<0.001), lopinavir (HR 3.58; 95% CI 3.02--4.25, p\<0.001), atazanavir (HR 1.71; 95% CI 1.48--1.97, p\<0.001), and raltegravir (HR 1.35; 95% CI 1.15--1.58, p\<0.001) (see [Fig 2](#pone.0171227.g002){ref-type="fig"}).

![Risk for treatment discontinuation in treatment-experienced patients (Treatment effects showing Hazard Ratios from univariate and multivariate Cox regression models).](pone.0171227.g002){#pone.0171227.g002}

Having a CD4 cell count \<200 μL or a viral load \>50 HIV-RNA copies/mL at treatment start significantly increased the risk for early treatment discontinuation in the adjusted analyses. Female gender, treatment line 4+ or treatment start 2011 or later also increased the risk. Similar to findings in treatment naive patients, heterosexual transmission route correlated to a lower risk and having a backbone other than ABC/3TCor TDF/FTC correlated to a higher risk for early discontinuation of the 3^rd^ agent. Treatment experienced patients with no backbone had a lower risk for early treatment discontinuation as well as patients with Asian origin. For complete results, see [Table 5](#pone.0171227.t005){ref-type="table"}.

10.1371/journal.pone.0171227.t005

###### Hazard Ratios from univariate and multivariate Cox regression models for treatment-experienced patients.

![](pone.0171227.t005){#pone.0171227.t005g}

  Covariate                        Value                                                            Distinct Patients (n)   Observations (n)   HR (95% CI) univariate model   P-value   HR (95% CI) multivariate model[\*](#t005fn001){ref-type="table-fn"}   P-value
  -------------------------------- ---------------------------------------------------------------- ----------------------- ------------------ ------------------------------ --------- --------------------------------------------------------------------- ---------
  Age                              Age \<50                                                         2081                    3144               Reference                                Reference                                                              
                                   Age ≥50                                                          951                     1403               0.95 (0.86;1.05)               0.308     0.97 (0.87;1.08)                                                      0.561
                                   Missing                                                          3                       5                  0.73 (0.18;2.93)               0.660     0.42 (0.10;1.68)                                                      0.219
  N\[t\]RTI Backbone               No Backbone                                                      211                     356                0.84 (0.70;1.01)               0.067     0.81 (0.66;0.99)                                                      0.038
                                   ABC/3TC                                                          1046                    1376               1.06 (0.96;1.17)               0.253     1.09 (0.98;1.21)                                                      0.128
                                   TDF/FTC                                                          1807                    2463               Reference                                Reference                                                              
                                   Other                                                            275                     357                1.39 (1.19;1.63)               \<0.001   1.21 (1.02;1.43)                                                      0.026
  CD4 cell count at baseline       ≤200                                                             414                     606                1.64 (1.44;1.88)               \<0.001   1.27 (1.08;1.49)                                                      0.004
                                   201--350                                                         732                     944                1.29 (1.14;1.46)               \<0.001   1.00 (0.87;1.14)                                                      0.978
                                   351--500                                                         826                     992                1.06 (0.93;1.20)               0.393     0.96 (0.84;1.09)                                                      0.495
                                   \>500                                                            1236                    1606               Reference                                Reference                                                              
                                   Missing                                                          358                     404                1.06 (0.88;1.27)               0.530     1.01 (0.83;1.24)                                                      0.898
  CDC Class                        C/AIDS                                                           520                     823                1.06 (0.95;1.19)               0.285     1.03 (0.91;1.16)                                                      0.630
                                   Non-C (i.e. A or B)                                              2482                    3729               Reference                                Reference                                                              
  Region of birth                  Sweden                                                           1190                    1816               Reference                                Reference                                                              
                                   Western Europe, USA, Israel, Canada, North Africa, Middle East   381                     576                1.01 (0.88;1.17)               0.858     1.07 (0.92;1.24)                                                      0.363
                                   Africa (East, South, West and Central)                           1024                    1598               1.02 (0.92;1.13)               0.722     0.97 (0.84;1.12)                                                      0.652
                                   Eastern Europe, Asia, Pacific, Caribbean, Latin America          363                     521                0.82 (0.69;0.96)               0.013     0.74 (0.62;0.88)                                                      \<0.001
                                   Missing                                                          33                      41                 0.58 (0.32;1.05)               0.072     0.73 (0.40;1.35)                                                      0.316
  Gender                           Male                                                             1779                    2651               Reference                                Reference                                                              
                                   Female                                                           1212                    1901               1.13 (1.03;1.24)               0.007     1.14 (1.01;1.29)                                                      0.030
  Hepatitis Status                 Negative                                                         2795                    4241               Reference                                Reference                                                              
                                   Hep B seropositive                                               61                      86                 0.74 (0.52;1.07)               0.108     0.81 (0.56;1.17)                                                      0.266
                                   Hep C seropositive                                               134                     213                1.30 (1.07;1.58)               0.009     1.03 (0.82;1.29)                                                      0.788
                                   Hep B+C seropositive                                             6                       12                 1.87 (0.93;3.74)               0.078     1.58 (0.78;3.20)                                                      0.204
  Transmission Route               Heterosexual                                                     1550                    2357               1.06 (0.95;1.17)               0.286     0.86 (0.74;0.99)                                                      0.039
                                   MSM                                                              960                     1454               Reference                                Reference                                                              
                                   IVDU                                                             220                     358                1.60 (1.36;1.88)               \<0.001   1.20 (0.99;1.46)                                                      0.066
                                   Other/unknown                                                    233                     353                1.09 (0.91;1.31)               0.357     0.88 (0.72;1.09)                                                      0.242
                                   Missing                                                          28                      30                 0.74 (0.35;1.55)               0.424     0.61 (0.28;1.30)                                                      0.199
  Treatment Start Year             2009--2010                                                       1309                    1654               Reference                                Reference                                                              
                                   2011--2012                                                       1286                    1617               0.95 (0.86;1.05)               0.319     1.23 (1.11;1.37)                                                      \<0.001
                                   2013--2014                                                       1084                    1281               0.83 (0.72;0.95)               0.006     1.32 (1.14;1.53)                                                      \<0.001
  Line of Therapy                  1[†](#t005fn002){ref-type="table-fn"}                            66                      66                 0.82 (0.54;1.23)               0.331     0.62 (0.41;0.94)                                                      0.023
                                   2                                                                1647                    1647               Reference                                Reference                                                              
                                   3                                                                1057                    1057               0.98 (0.87;1.11)               0.752     1.09 (0.96;1.24)                                                      0.169
                                   4+                                                               1119                    1782               1.09 (0.98;1.21)               0.113     1.37 (1.19;1.56)                                                      \<0.001
  Baseline Viral Load              \<50                                                             2021                    2613               Reference                                Reference                                                              
                                   51--1,000                                                        517                     658                1.37 (1.20;1.56)               \<0.001   1.25 (1.09;1.44)                                                      0.001
                                   1,001--10,000                                                    267                     338                1.83 (1.56;2.14)               \<0.001   1.59 (1.34;1.88)                                                      \<0.001
                                   10,001--100,000                                                  408                     512                1.49 (1.30;1.72)               \<0.001   1.21 (1.04;1.41)                                                      0.014
                                   \>100,000                                                        226                     291                1.92 (1.63;2.26)               \<0.001   1.46 (1.21;1.75)                                                      \<0.001
                                   Missing                                                          124                     140                1.26 (0.98;1.63)               0.073     1.00 (0.76;1.33)                                                      0.973
  3rd Agent                        Efavirenz                                                        668                     694                1.51 (1.30;1.74)               \<0.001   1.86 (1.59;2.17)                                                      \<0.001
                                   Etravirine                                                       243                     262                1.53 (1.26;1.87)               \<0.001   1.61 (1.31;1.98)                                                      \<0.001
                                   Rilpivirine                                                      584                     592                0.60 (0.48;0.74)               \<0.001   0.66 (0.52;0.83)                                                      \<0.001
                                   Lopinavir                                                        271                     291                3.42 (2.92;4.01)               \<0.001   3.58 (3.02;4.25)                                                      \<0.001
                                   Atazanavir                                                       720                     806                1.54 (1.35;1.77)               \<0.001   1.71 (1.48;1.97)                                                      \<0.001
                                   Darunavir                                                        1200                    1285               Reference                                Reference                                                              
                                   Raltegravir                                                      594                     622                1.29 (1.10;1.51)               0.001     1.35 (1.15;1.58)                                                      \<0.001
  Years Since Start of first ART   0--2 years                                                       1062                    1413               Reference                                Reference                                                              
                                   3--5 years                                                       535                     623                0.87 (0.75;1.00)               0.057     0.87 (0.75;1.02)                                                      0.078
                                   5+ years                                                         1668                    2516               0.85 (0.77;0.94)               0.002     0.78 (0.68;0.88)                                                      \<0.001

\* Adjustments made for treatment, age, gender, ethnicity, CD4 count at treatment baseline, viral load at baseline, CDC class, route of infection, year of initiation treatment, years since start 1st treatment, line of therapy, hepatitis status, and N\[t\]RTI Backbone treatment.

†Patients with a prior treatment episode with only N\[t\]RTIs and starting their first treatment including a 3^rd^ agent during the study period 2009--2014

Discussion {#sec019}
==========

As HIV infection needs lifelong treatment, studying treatment duration and factors influencing treatment durability is crucial. This can be done in randomized clinical trials but, for several reasons, a real life cohort study like ours can give additional benefits.

First, in a randomized clinical trial you study a selected, small, homogeneous patient group in a strictly standardized setting in order to be able to attribute the effect to the specific intervention, for example, the efficacy of a drug. This might lead to results less applicable outside the study setting \[[@pone.0171227.ref007]\]. In the present study we had the unique opportunity to be able to study the effectiveness of the most used HIV treatments in an entire national real world HIV cohort.

Second, in a randomized clinical trial you exclude the possibility for the physician to use his clinical expertise to individualize the treatment according to patient characteristics. As example, in several clinical studies, efavirenz has been shown to have CNS side effects leading to drug discontinuation in a significant number of patients \[[@pone.0171227.ref014]--[@pone.0171227.ref016]\]. In the clinical setting the physician can decrease the risk for discontinuations by not using efavirenz in patients with factors known to increase the risk for neuropsychiatric side effects \[[@pone.0171227.ref017]--[@pone.0171227.ref019]\].

Third, a real world cohort gives the possibility to have a significantly longer observation period than in prospective clinical studies. In this study we followed patients up to 6 years which rarely occurs in a clinical trial.

The overall treatment discontinuation rate in this study was similar for treatment naive and treatment experienced patients; 10% of the patients discontinued the 3^rd^ agent within 3 months and a quarter within one year. However, the differences between drugs were significant with discontinuation rates one year after start of treatment of more than 50% in lopinavir patients compared to approximately 10% in rilpivirine patients. It is also noticeable that different drugs in the same class of drugs can perform very differently. This indicates that comparisons between classes of HIV drugs do not take into account the specific characteristics of the individual ARVs and therefore can be misleading.

We found that the selection of a 3^rd^ agent seemed to have a stronger influence on treatment duration than demographic or clinical factors. Both in treatment-naïve and treatment-experienced patients, rilpivirine had a significantly lower risk for early treatment discontinuation compared to the other drugs studied. There may be several factors contributing to this. In treatment-naïve patients starting on rilpivirine very few had an HIV-RNA \>100 000 copies/ml at start of treatment confirming its use according to label, very few had low CD4 cell counts and none of the patients had an AIDS diagnosis. In treatment-experienced patients starting rilpivirine a high proportion, 87% of the patients, had a viral load below 50 copies/ml at baseline indicating that the main reasons for switch were tolerability issues or simplification. Both in treatment-naive and treatment-experienced analyses rilpivirine still had a significantly lower risk of discontinuation when adjusted for these factors but it is still not possible to rule out an unmeasured bias e.g. the prescribing physicians estimation of the patient adherence level. Our interpretation is that the superiority shown for rilpivirine is partly due to channeling bias where rilpivirine was chosen for being easy to treat patients with an anticipated good adherence, but its favorable side effect profile shown in phase 3 studies also was a contributing factor \[[@pone.0171227.ref020],[@pone.0171227.ref021]\].

Both in treatment-naïve and in treatment-experienced patients starting lopinavir, there was a significant higher risk for early treatment discontinuation compared to all other drugs studied. A plausible explanation is that early in the study period lopinavir was no longer recommended in the Swedish HIV treatment guidelines because of its less favorable gastro-intestinal side effect profile and its more pronounced negative effect on blood lipids compared to the two other recommended protease inhibitors darunavir and atazanavir \[[@pone.0171227.ref011]\]. Together with the need for twice daily dosing this may have accelerated the switch rate from lopinavir. Also, a relatively high proportion of patients, 40% of naive and 24% of treatment-experienced who used lopinavir did not use or tenofovir disoproxil fumarate/emtricitabine as N\[t\]RTI backbone treatment, but other (older) combinations which may have further contributed to the poorer result seen. The high use of other backbone combinations may in part be explained by more women taking lopinavir indicating usage during pregnancy.

Treatment durations for efavirenz, darunavir and atazanavir were similar in treatment-naive patients but raltegravir had a significantly higher risk of early treatment discontinuation. In the STARTMRK study patients on raltegravir had significantly fewer drug related adverse events than patients on efavirenz \[[@pone.0171227.ref022]\]. In our present study naive patients starting efavirenz showed lower risk for early drug discontinuation compared to raltegravir. One explanation may be that physicians followed the recommendation in Swedish treatment guidelines not to initiate efavirenz treatment in patients with psychiatric problems thereby avoiding some treatment discontinuations due to neuropsychiatric adverse events.

In treatment-experienced patients darunavir, the most commonly used 3^rd^ agent during our study period, showed a significantly lower risk for treatment discontinuation than all other ARVs, except for rilpivirine. In line with clinical trials results our interpretation is that this is a reflection of its favorable side effect profile, compared to other boosted protease inhibitors, together with high efficacy and low risk for resistance development across different patient types \[[@pone.0171227.ref023], [@pone.0171227.ref024]\]. In treatment-experienced patients a high genetic barrier and a low risk for resistance development is of importance if the switch is because of previous treatment failure or sub-optimal adherence \[[@pone.0171227.ref025], [@pone.0171227.ref026]\].

In line with other reports this study confirms that, besides the ARV chosen, certain baseline characteristics of patients are independently associated with differences in treatment duration \[[@pone.0171227.ref027]--[@pone.0171227.ref030]\]. In naive patients we found that AIDS diagnosis and the use of other backbone than ABC/3TCor TDF/FTC increased the risk for early treatment discontinuation. Heterosexual transmission category decreased the risk in comparison to MSM. In treatment-experienced patients, indicators of viral failure or a highly treatment experienced patient increased the risk for early treatment discontinuation; CD4 cell count \<200, use of other backbone than ABC/3TC orTDF/FTC, being on 4^th^ or higher line of treatment or having viral load \>50 copies ml at start of treatment. In both treatment-naive and treatment-experienced patients, a start of treatment in 2011 or later was correlated to an earlier treatment discontinuation. One possible explanation is that in this time period we had a higher switch rate from older drugs like lopinavir and newer drugs like rilpivirine, elvitegravir and dolutegravir were introduced.

There are several limitations with our study the most important being that we cannot provide the reasons for drug discontinuations. Both viral failure with development of resistance associated mutations and some drug toxicities may limit future treatment options while this is not the case in treatment modifications to lower pill burden or to have less frequent dosing.

We also did not have any data on the level of adherence. Neither measurements of adherence nor physician\`s estimates of adherence were available. Estimated or observed adherence probably has an important impact on the choice of new treatment regimens. Another limitation is that not all kinds of data are included in InfCareHIV. It would have been of interest to see e.g. how socioeconomic factors like education, employment, income, marital status, active drug use influence drug duration time.

Last, the data and the results are mostly applicable to the time period studied and to Sweden or other countries with a similar health care environment. Sweden is a country with a low HIV prevalence, and the care of HIV patients in Sweden is highly specialized; all HIV infected patients are linked to specialized HIV care centers with dedicated multidisciplinary teams of physicians, nurses and social workers, Following the Swedish law of Communicable Disease Act all HIV drugs and HIV health care are freely available for patients but also obliges the patients to keep regular contact with the responsible HIV clinic. All this are contributing to the excellent treatment outcomes in Swedish HIV patients, and we believe Sweden is the first country to achieve the UNAIDS/WHO 90-90-90 targets \[[@pone.0171227.ref031]\].

In conclusion, we found that selection of the 3^rd^ agent is an important factor to maximize treatment duration. The choice of backbone, ABC/3TCorTDF/FTC, had no effect on 3^rd^ agent duration. Individualizing treatment can avoid some toxicity discontinuations, e.g. efavirenz and CNS side effects. Use of rilpivirine in naïve patients is associated with long treatment duration if use in patients with high viral load or advanced disease is avoided. The same applies to treatment-experienced patients who switch to rilpivirine with undetectable viral load. In treatment-experienced patients darunavir was the mostly used drug and, besides rilpivirine, also showed the lowest risk for treatment discontinuation.
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